Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 12/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840755 | 0.83 | SLC22A12 (0.41) | SLC22A12ARCYP11B1CYP11B2 | |
| SCHEMBL21840770 | 0.76 | SLC22A12 (0.65) | SLC22A12ARPGRCYP11B1CYP11B2 | |
| SCHEMBL19066207 | 0.75 | SLC22A12 (0.41) | SLC22A12ARELANE | |
| SCHEMBL21840742 | 0.70 | SLC22A12 (0.59) | SLC22A12ARCYP11B1CYP11B2 | |
| SCHEMBL343412 | 0.68 | CA2 (0.37) | ARTAS2R14PGRCYP11B1CYP11B2 | |
| SCHEMBL19066197 | 0.66 | SLC22A12 (0.40) | SLC22A12ARPGR | |
| SCHEMBL12151755 | 0.65 | AR (0.52) | ARTAS2R14CYP11B1CYP11B2PTPN1 | |
| SCHEMBL29546917 | 0.65 | AR (0.52) | ARTAS2R14CYP11B1CYP11B2PTPN1 | |
| SCHEMBL4594768 | 0.65 | AR (0.47) | ARTAS2R14PGRPTPN1PTPN6 | |
| SCHEMBL20596597 | 0.65 | KIF11 (0.44) | ARTAS2R14CYP11B1CYP11B2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397627-B1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-108699027-B | Indolizine derivatives, compositions and methods of use | 重庆复创医药研究有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD. (CN) | 2021-01-19 | — | — | US | disclosed |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | INMT, SLC14A1, AADAT | SLC22A12 569/4885AR 1099/4885TAS2R14 3279/4885 |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | INMT, SLC14A1, AADAT | SLC22A12 569/4885AR 1099/4885TAS2R14 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.